Table 2.
Efficacies of induction therapy in 20 previously reported patients with anti-GAD antibodies associated cerebellar ataxia. Data based on short-term follow-up
| High responders | Low responders | No change | Sum | |
|---|---|---|---|---|
| Subacute type | ||||
| mPSL | 2 | 0 | 0 | 2 |
| IVIg + PE | 0 | 0 | 1 | 1 |
| IVIg + R | 1 | 0 | 0 | 1 |
| PE + R | 1 | 0 | 1 | 2 |
| Sum | 4 | 0 | 2 | 6 |
| Chronic type | ||||
| mPSL | 2 | 1 | 2 | 5 |
| mPSL + IVIg | 0 | 1 | 0 | 1 |
| mPSL + PE | 1 | 1 | 0 | 2 |
| oral PSL | 0 | 1 | 0 | 1 |
| IVIg | 3 | 1 | 2 | 6 |
| IVIg + R | 0 | 1 | 1 | 2 |
| PE | 2 | 0 | 0 | 2 |
| Sum | 8 | 6 | 5 | 19a |
aSince two of 14 patients were repeatedly treated due to relapse, the number of therapies was 19.
mPSL intravenous methylprednisolone, oral PSL oral prednisolone, IVIg intravenous immunoglobulins, PE plasma exchange, R rituximab